Study of AZD0120 for multiple myeloma patients
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma using standard criteria.
- You are in good physical condition (ECOG score 0 or 1).
- Your organs and bone marrow are working well enough.
- If newly diagnosed, you have had little or no prior treatment.
- If your myeloma has come back or didn't respond to treatment, you have had 1 or 2 prior therapies including a proteasome inhibitor and an IMiD drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.